pharma · Heart Failure · Atrial Fibrillation · RYTM
Rhythm Pharmaceuticals Netherlands
Rhythm Pharmaceuticals Netherlands B.V.
Matisse Pharmaceuticals is a pharma organization headquartered in geleen, NL. It trades on NYSE under ticker RYTM. Primary therapeutic focus areas include Heart Failure, Atrial Fibrillation, Hypothalamic Obesity, Paroxys
BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl HQ
2014 Founded
10 Employees
Public company Type
RYTM · NYSE Ticker
Company details
- Status
- Public
- HQ
- BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl
- Founded
- 2014
- Employees
- 10
- Programs
- 73
- Drugs
- 38
- Patents
- 12
Flecainide or Sotalol or Propafenone
Phase 3 · small molecule · Paroxysmal Atrial Fibrillation
Flecainide or Sotalol or Propafenone for Paroxysmal Atrial Fibrillation is a Phase 3 program (small_molecule) at Rhythm Pharmaceuticals Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code PS-023
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Rhythm Pharmaceuticals Netherlands B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Paroxysmal Atrial Fibrillation
- Status
- completed
- Trials
- 1